T. Rowe Price Associates’s Aspen Aerogels ASPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$367K Buy
107,300
+9,001
+9% +$30.3K ﹤0.01% 2576
2025
Q4
$279K Buy
98,299
+21,673
+28% +$112K ﹤0.01% 2675
2025
Q3
$534K Buy
76,626
+5,749
+8% +$40.5K ﹤0.01% 2329
2025
Q2
$420K Buy
70,877
+4,502
+7% +$25.9K ﹤0.01% 2382
2025
Q1
$425K Buy
66,375
+23,924
+56% +$231K ﹤0.01% 2318
2024
Q4
$505K Buy
42,451
+11,688
+38% +$199K ﹤0.01% 2274
2024
Q3
$852K Buy
30,763
+8,877
+41% +$222K ﹤0.01% 2040
2024
Q2
$522K Buy
21,886
+7,306
+50% +$171K ﹤0.01% 2176
2024
Q1
$257K Buy
14,580
+1,938
+15% +$28.6K ﹤0.01% 2507
2023
Q4
$200K Buy
12,642
+674
+6% +$6.96K ﹤0.01% 2546
2023
Q3
$103K Buy
11,968
+1,280
+12% +$9.09K ﹤0.01% 2662
2023
Q2
$85K Buy
+10,688
New +$74.4K ﹤0.01% 2722
2022
Q1
Sell
-375,968
Closed -$18.7M 2979
2021
Q4
$18.7M Sell
375,968
-76,862
-17% -$4.05M ﹤0.01% 1300
2021
Q3
$20.8M Sell
452,830
-54,254
-11% -$2.15M ﹤0.01% 1286
2021
Q2
$15.2M Sell
507,084
-89,683
-15% -$1.83M ﹤0.01% 1362
2021
Q1
$12.1M Buy
596,767
+3,458
+0.6% +$72.9K ﹤0.01% 1363
2020
Q4
$9.9M Buy
593,309
+12,743
+2% +$168K ﹤0.01% 1352
2020
Q3
$6.36M Buy
+580,566
New +$4.59M ﹤0.01% 1375
2016
Q4
Sell
-2,721,240
Closed -$16.2M 2549
2016
Q3
$16.2M Sell
2,721,240
-22,500
-0.8% -$113K ﹤0.01% 1202
2016
Q2
$13.6M Sell
2,743,740
-3,240
-0.1% -$14.2K ﹤0.01% 1221
2016
Q1
$12.4M Buy
2,746,980
+537,410
+24% +$2.44M ﹤0.01% 1219
2015
Q4
$13.4M Buy
2,209,570
+676,150
+44% +$4.68M ﹤0.01% 1213
2015
Q3
$11.5M Sell
1,533,420
-210
-0% -$1.53K ﹤0.01% 1271
2015
Q2
$10.2M Buy
1,533,630
+8,700
+0.6% +$59.5K ﹤0.01% 1344
2015
Q1
$11.1M Buy
1,524,930
+117,010
+8% +$886K ﹤0.01% 1310
2014
Q4
$11.2M Buy
1,407,920
+1,100
+0.1% +$9.34K ﹤0.01% 1293
2014
Q3
$14.2M Buy
1,406,820
+83,030
+6% +$841K ﹤0.01% 1214
2014
Q2
$14.6M Buy
+1,323,790
New +$14.4M ﹤0.01% 1214

Other funds holding ASPN

T. Rowe Price Associates's ASPN Position: Q1 2026 in Review

T. Rowe Price Associates increased its Aspen Aerogels (ASPN) stake by 9.2% in Q1 2026, buying an estimated $30.3K and bringing the position to 107,300 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #2576.

T. Rowe Price Associates first reported a position in ASPN in Q2 2014 and has held it in 28 quarters since. The position peaked at $20.8M in Q3 2021. 166 funds tracked by Wall St. Rank hold ASPN as of Q1 2026.

  • T. Rowe Price Associates held 107,300 shares of Aspen Aerogels worth $367K as of Q1 2026.
  • T. Rowe Price Associates bought 9,001 Aspen Aerogels shares in Q1 2026, an estimated $30.3K.
  • Aspen Aerogels made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2576 holding.
  • T. Rowe Price Associates first reported a position in Aspen Aerogels in Q2 2014 and has held it in 28 quarters since.
  • T. Rowe Price Associates's Aspen Aerogels position peaked at $20.8M in Q3 2021.
  • 166 funds tracked by Wall St. Rank held Aspen Aerogels as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.